Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Amgen acquires Dark Blue Therapeutics to advance first-in-class AML program

Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.

The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

Leia mais: Amgen acquires Dark Blue Therapeutics to advance first-in-class AML program
Grafa
Health

Actuate Therapeutics announces strong clinical activity in refractory pediatric cancers

Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.

The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.

Leia mais: Actuate Therapeutics announces strong clinical activity in refractory pediatric cancers
Grafa
Agriculture

Edible Garden preliminary holiday sales surge 26% amid retail expansion

Edible Garden AG Incorporated (NASDAQ:EDBL) reported a 26.4% year-over-year increase in preliminary sales for the 2025 holiday period on January 6, 2026.

The gains were driven by robust demand for its core "Controlled Environment Agriculture" (CEA) products and a rapidly expanding retail footprint that now exceeds 5,000 locations across the U.S., Caribbean, and South America.

Leia mais: Edible Garden preliminary holiday sales surge 26% amid retail expansion
Grafa
Health

TransCode Therapeutics reports breakthrough glioblastoma data; Phase 2a set for H1 2026

TransCode Therapeutics (NASDAQ:RNAZ) today announced positive preclinical data demonstrating that its lead candidate, TTX-MC138, successfully reaches orthotopic glioblastoma tumors following intravenous administration and achieves sustained target engagement against miR-10b.

Leia mais: TransCode Therapeutics reports breakthrough glioblastoma data; Phase 2a set for H1 2026
Grafa
Health

Lockheed Martin signs landmark deal to triple Patriot (PAC-3 MSE) production

Lockheed Martin (NYSE:LMT) announced a transformative seven-year framework agreement with the U.S. Department of War on January 6, 2026.

The deal is designed to more than triple the annual production capacity of the PAC-3® Missile Segment Enhancement (MSE) interceptor, surging from current levels of approximately 600 units to a target of 2,000 units per year.

The agreement is a flagship outcome of the Department of War’s new Acquisition Transformation Strategy.

By providing long-term "demand certainty," the framework incentivizes Lockheed Martin and its massive global supply chain to invest in expanded tooling, facilities, and workforce.

To manage the financial burden of such a rapid scale-up, the deal utilizes a "collaborative financing model" that aims for cash neutrality in the early stages, allowing Lockheed to fund the expansion without immediate pressure on its balance sheet.

This "surging" of the "Arsenal of Freedom" follows a record-breaking 2025, where Lockheed Martin delivered 620 PAC-3 MSEs—a 20% year-over-year increase.

The PAC-3 MSE is a "hit-to-kill" interceptor, meaning it uses pure kinetic energy rather than a blast-fragmentation warhead to neutralize threats, making it the premier defense against advanced ballistic missiles, cruise missiles, and emerging hypersonic threats.

Leia mais: Lockheed Martin signs landmark deal to triple Patriot (PAC-3 MSE) production
Grafa
Health

Johns Hopkins treats first commercial prostate cancer patient with Profound Medical's TULSA-PRO system

Profound Medical Corp. (NASDAQ:PROF) on Tuesday announced that Johns Hopkins Hospital has performed its first commercial prostate cancer treatment using the company's TULSA-PRO system, marking a key adoption milestone for the MRI-guided, incision-free ablation technology.

Leia mais: Johns Hopkins treats first commercial prostate cancer patient with Profound Medical's TULSA-PRO system